In a strategic move designed to revolutionize the diagnostic landscape for chronic respiratory conditions, bioAffinity Technologies has entered into a formal collaboration with Pictor to develop and commercialize a new generation of diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD). This partnership represents a convergence of two distinct but highly complementary biotechnological approaches: bioAffinity’s specialized expertise in sputum analysis and flow cytometry, and Pictor’s advanced proteomic platform. By integrating these technologies, the companies aim to provide clinicians with a comprehensive assessment of airway inflammation, enabling more precise, personalized treatment plans for millions of patients suffering from chronic lung diseases.
The collaboration focuses on the creation of a high-throughput laboratory test capable of identifying specific inflammatory pathways at a granular level. Currently, many patients with asthma or COPD are treated using a "one-size-fits-all" approach, which may not account for the underlying biological drivers of their specific condition. The new diagnostic tool is expected to bridge this gap, allowing physicians to distinguish between various inflammatory phenotypes and select the most effective therapies, including high-cost biologics that have recently received approval from the U.S. Food and Drug Administration (FDA).
Technical Synergy: Combining Flow Cytometry and Proteomics
The core of the collaboration lies in the integration of bioAffinity’s proprietary knowledge of immune cell populations with Pictor’s multiplexed proteomic capabilities. bioAffinity Technologies has long been a leader in the non-invasive analysis of sputum—the mucus coughed up from the lower airways. Their methodology involves using flow cytometry to differentiate and quantify various immune cell populations, such as eosinophils, neutrophils, and macrophages, which are central to the inflammatory response in the lungs.
Pictor, on the other hand, provides a targeted proteomic platform that allows for the simultaneous analysis of multiple biomarkers, specifically cytokines. Cytokines are small proteins that act as chemical messengers in the immune system; in the context of asthma and COPD, specific cytokine profiles can indicate whether a patient’s inflammation is driven by Type 2 (Th2) immune responses or other pathways.
By combining cellular data (from bioAffinity) with molecular signaling data (from Pictor), the resulting diagnostic platform will offer a multi-dimensional view of a patient’s respiratory health. This "dual-lens" approach is expected to significantly enhance the accuracy of lung inflammation assessments compared to traditional single-analyte tests, which often provide an incomplete picture of the disease state.
Addressing a Global Health Crisis: The Burden of Asthma and COPD
The clinical need for better respiratory diagnostics is underscored by the staggering global prevalence of asthma and COPD. According to the World Health Organization (WHO), asthma affected an estimated 262 million people in 2019 and caused nearly 455,000 deaths. COPD is even more prevalent and lethal, currently ranking as the third leading cause of death worldwide, accounting for over 3 million deaths annually.
In the United States, the economic burden is equally significant. The Centers for Disease Control and Prevention (CDC) notes that asthma accounts for billions of dollars in direct medical costs and lost productivity every year. For COPD, the costs are even higher, largely due to frequent hospitalizations and the long-term management of chronic symptoms. Despite these numbers, diagnosis and management remain challenging. Many patients are misdiagnosed, and even those with a correct diagnosis often struggle to find a treatment regimen that effectively controls their symptoms.
The bioAffinity-Pictor collaboration aims to address these challenges by providing a tool that moves beyond simple symptom management. By identifying the specific biological drivers of a patient’s inflammation, the new tests will allow for "precision medicine" in respiratory care—ensuring the right patient gets the right drug at the right time.
Enhancing Clinical Decision-Making for Advanced Biologics
One of the most significant implications of this new diagnostic platform is its potential to guide the use of advanced biological therapies. In recent years, the FDA has approved several biologics for the treatment of severe asthma, such as those targeting interleukin-5 (IL-5) or interleukin-4/13 (IL-4/13). While these drugs can be life-changing for the right patients, they are also expensive and are only effective in specific inflammatory phenotypes.
Currently, clinicians often rely on blood eosinophil counts or fractional exhaled nitric oxide (FeNO) tests to determine if a patient is a candidate for biologics. However, these markers can be inconsistent and do not always reflect the actual environment within the lungs. A sputum-based test that analyzes both cells and cytokines provides a direct measurement of the "ground zero" of the disease.
"The resulting high-throughput laboratory test will support physicians in identifying inflammatory pathways relevant to each patient," the companies stated in a joint release. This capability is expected to be a game-changer for specialists who must decide whether to escalate a patient to biologics or stick with traditional inhaled corticosteroids and long-acting beta-agonists.
Operational Efficiency and Economic Viability
Beyond the clinical benefits, the partnership is focused on the economic realities of modern laboratory medicine. Maria Zannes, President and CEO of bioAffinity Technologies, highlighted the operational advantages of Pictor’s technology in the partnership announcement.
"Pictor’s targeted proteomic platform has the ability to lower our operating costs compared with traditional single-analyte testing by improving laboratory efficiency and reducing testing complexity," Zannes noted. "This is required to serve a large and growing market like that of asthma and COPD. We look forward to taking advantage of Pictor’s expertise in proteomics and product development, and their team’s experience in optimizing laboratory-friendly workflows to facilitate high-throughput testing."
By automating and multiplexing the testing process, the companies can process a higher volume of samples with greater precision and lower overhead. This efficiency is critical for widespread adoption, as it ensures that the tests can be offered at a price point that is sustainable for both healthcare providers and payers.
Chronology and Development Roadmap
The collaboration between bioAffinity and Pictor is built upon a foundation of existing intellectual property and previous successes. bioAffinity Technologies is already well-known for its CyPath® Lung test, a non-invasive diagnostic used by clinicians to assess the risk of malignancy in pulmonary nodules. The CyPath® Lung technology also utilizes flow cytometry and sputum analysis, providing a proven framework for the new asthma and COPD tests.
The development timeline for the new respiratory tests is expected to follow an accelerated path. The companies intend to introduce the tests initially as Laboratory Developed Tests (LDTs) under the Clinical Laboratory Improvement Amendments (CLIA). This regulatory pathway allows high-complexity laboratories to develop and validate tests in-house, providing a faster route to market than the traditional Premarket Approval (PMA) process required for distributed kits, while still maintaining rigorous standards for clinical validity and utility.
As the development progresses, the companies will conduct clinical validation studies to demonstrate the test’s ability to accurately phenotype asthma and COPD patients and predict response to specific therapies. These data sets will be crucial for securing reimbursement from insurance providers and gaining traction among pulmonologists and allergists.
Intellectual Property and Strategic Alignment
The agreement between the two firms includes a clear framework for the ownership of intellectual property (IP). According to the terms, any IP arising from the collaboration specifically related to the asthma and COPD testing platform will be owned by bioAffinity Technologies. This ensures that bioAffinity can continue to build its portfolio of respiratory diagnostic solutions.
Conversely, Pictor will retain all rights to its proprietary proteomic platform technology and any inventions related to the underlying system. This arrangement allows Pictor to leverage its technology across other therapeutic areas while benefiting from the commercial success of the respiratory tests developed in tandem with bioAffinity.
This strategic alignment suggests a long-term commitment to the partnership. By sharing the risks and rewards of development, both companies are positioned to capitalize on the growing demand for precision diagnostics in the multi-billion-dollar respiratory health market.
Broader Impact: Shifting the Paradigm of Lung Health
The collaboration between bioAffinity Technologies and Pictor is more than just a business deal; it represents a shift in the paradigm of lung health management. For decades, respiratory medicine has lagged behind oncology in the adoption of precision diagnostics. In cancer care, molecular profiling of tumors is standard practice to guide therapy. In respiratory care, clinicians have largely relied on physiological measures like spirometry, which measure how well a patient breathes but not why they are struggling to breathe.
By bringing proteomic and cellular analysis to the forefront of asthma and COPD care, bioAffinity and Pictor are helping to usher in an era where lung diseases are treated based on their unique molecular signatures. This shift has the potential to reduce hospitalizations, decrease the side effects associated with ineffective treatments, and ultimately improve the quality of life for millions of people.
Furthermore, the focus on non-invasive sputum analysis is a significant patient-centric advantage. Unlike invasive procedures such as bronchoscopy, which requires sedation and carries risks, providing a sputum sample is simple and safe for the patient. This ease of use encourages more frequent monitoring, allowing doctors to adjust treatments in real-time as a patient’s inflammatory profile changes over time.
Conclusion: A New Standard for Respiratory Diagnostics
As bioAffinity Technologies and Pictor move forward with their development plans, the medical community will be watching closely. The promise of a high-throughput, cost-effective, and highly accurate diagnostic test for asthma and COPD phenotypes addresses a critical unmet need in global healthcare.
With the combination of bioAffinity’s deep understanding of lung biology and Pictor’s cutting-edge proteomic tools, the partnership is well-equipped to overcome the technical and economic hurdles of diagnostic development. If successful, these new tests will not only support the clinical use of biologics but will also set a new standard for how chronic airway diseases are diagnosed, monitored, and treated in the 21st century.
The initial launch under CLIA regulations will mark the first major milestone in this journey, potentially providing clinicians with a powerful new tool in the fight against some of the world’s most prevalent and debilitating respiratory conditions. Through this collaboration, bioAffinity and Pictor are not just developing a product; they are creating a pathway toward a more personalized and effective future for respiratory medicine.
